Analysis of the cost-effectiveness of treatment strategies for CML with incorporation of treatment discontinuation-Reference-Cited by-同舟云学术

Analysis of the cost-effectiveness of treatment strategies for CML with incorporation of treatment discontinuation

Published:2019-10-31 Issue:21 Volume:3 Page:3266-3277
ISSN:2473-9529
Container-title:Blood Advances
language:en
Short-container-title:

Author:

Yamamoto Chihiro¹^ORCID,Nakashima Hirotomo¹,Ikeda Takashi¹,Kawaguchi Shin-ichiro¹,Toda Yumiko¹,Ito Shoko¹,Mashima Kiyomi¹,Nagayama Takashi¹,Umino Kento¹,Minakata Daisuke¹,Nakano Hirofumi¹,Morita Kaoru¹,Yamasaki Ryoko¹,Sugimoto Miyuki¹,Ishihara Yuko¹,Ashizawa Masahiro¹,Hatano Kaoru¹,Sato Kazuya¹,Oh Iekuni¹,Fujiwara Shin-ichiro¹,Ueda Masuzu¹,Ohmine Ken¹,Muroi Kazuo¹²,Kanda Yoshinobu¹

Affiliation:

1. Division of Hematology, Department of Medicine, and

2. Division of Cell Transplantation and Transfusion, Jichi Medical University, Shimotsuke, Japan

Abstract

Key Points The cost of TKI for treatment of CML can be substantially saved by treatment discontinuation in patients who achieved DMR. Starting treatment with imatinib is the most cost-effective strategy even after incorporation of treatment discontinuation.

Publisher

American Society of Hematology

Subject

Hematology

Link

http://ashpublications.org/bloodadvances/article-pdf/3/21/3266/1505899/advancesadv2019000745.pdf

Reference32 articles.

1. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia;Druker;N Engl J Med,2006

2. Long-term outcomes of imatinib treatment for chronic myeloid leukemia;Hochhaus;N Engl J Med,2017

3. Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034;Shah;Am J Hematol,2016

4. Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study;Giles;Leukemia,2013

5. Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naive chronic myeloid leukemia patients trial;Cortes;J Clin Oncol,2016

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Markov analysis of azacitidine and venetoclax vs induction chemotherapy for medically fit patients with AML;Blood Advances;2024-02-13

2. Maximizing the Value of Chronic Myeloid Leukemia Management Using Tyrosine Kinase Inhibitors in the USA: Potential Determinants and Consequences of Healthcare Resource Utilization and Costs, with Proposed Optimization Approaches;Clinical Drug Investigation;2024-01-05

3. Patient Versus Physician Perspective in the Management of Chronic Myeloid Leukemia During Treatment with Tyrosine Kinase Inhibitors;Oncology and Therapy;2023-12-16

4. Evaluation of physician guideline adherence and areas for improvement in managing patients with chronic myeloid leukemia: a cross-sectional survey;Leukemia & Lymphoma;2023-06-06

5. Importance of TKI treatment duration in treatment-free remission of chronic myeloid leukemia: results of the D-FREE study;International Journal of Hematology;2023-02-04